Updates are available Correction dated 2021-11-17
Click to view Correction: https://doi.org/10.1038/s41596-021-00525-1
-
Authors
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
- License Information
-
More Information
Article History
Received: 21 May 2020
Accepted: 20 October 2020
First Online: 18 January 2021
Change Date: 17 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41596-021-00525-1
Competing interests
: The authors declare competing financial interests. D.R.L. is a consultant and co-founder of Prime Medicine, Beam Therapeutics, Pairwise Plants and Editas Medicine, companies that use genome editing. The authors are co-inventors on patent applications on base editing.
